Literature DB >> 6095707

Lung asbestos content in chrysotile workers with mesothelioma.

A Churg, B Wiggs, L Depaoli, B Kampe, B Stevens.   

Abstract

The role of chrysotile asbestos in the genesis of mesotheliomas in humans is disputed. We analyzed the asbestos content of the lung in 6 long-term chrysotile miners and millers who had pleural mesotheliomas. In five patients, only chrysotile ore components (chrysotile and tremolite/actinolite/anthophyllite types of amphibole asbestos) were found, while the sixth patient presented both chrysotile ore components and amosite, a type of asbestos that is not derived from the mining process. The mean number of fibers/g dry lung for the 5 patients with mesothelioma containing only chrysotile ore components was higher (chrysotile 64 X 10(6) and tremolite group 540 X 10(6] than in a group of long-term chrysotile miner control subjects who had no asbestos-related disease (chrysotile 23 X 10(6), tremolite group 58 X 10(6], but some patients with mesothelioma had fiber burdens near the mean of the control range. Fiber sizes and aspect ratios in the mesothelioma group were approximately the same as those in the control subjects, and analysis of fiber distribution failed to show any preferential localization in the periphery of the lung. However, the concentration ratio of tremolite in the lungs of the mesothelioma cases compared to the control cases was 9.3, while the ratio of chrysotile was only 2.8. Our findings provide strong evidence that chrysotile mine dust (chrysotile and amphibole components) can produce mesotheliomas in humans; the greater relative amounts of tremolite group amphiboles present in the patients with mesothelioma raise the possibility that these fibers may be important in the pathogenesis of the tumors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6095707     DOI: 10.1164/arrd.1984.130.6.1042

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  26 in total

1.  Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region.

Authors:  D Howel; A Gibbs; L Arblaster; L Swinburne; M Schweiger; E Renvoize; P Hatton; F Pooley
Journal:  Occup Environ Med       Date:  1999-01       Impact factor: 4.402

Review 2.  Role of asbestos and other fibres in the development of diffuse malignant mesothelioma.

Authors:  A R Gibbs
Journal:  Thorax       Date:  1990-09       Impact factor: 9.139

Review 3.  Malignant mesothelioma.

Authors:  R Rudd
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

4.  Mesothelioma in Cyprus: the role of tremolite.

Authors:  K McConnochie; L Simonato; P Mavrides; P Christofides; F D Pooley; J C Wagner
Journal:  Thorax       Date:  1987-05       Impact factor: 9.139

Review 5.  Cellular and molecular parameters of mesothelioma.

Authors:  Maria E Ramos-Nino; Joseph R Testa; Deborah A Altomare; Harvey I Pass; Michele Carbone; Maurizio Bocchetta; Brooke T Mossman
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

6.  Analysis of lung asbestos content.

Authors:  A Churg
Journal:  Br J Ind Med       Date:  1991-10

Review 7.  Analysis and interpretation of inorganic mineral particles in "lung" tissues.

Authors:  A R Gibbs; F D Pooley
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

Review 8.  Assessment of mineral fibres from human lung tissue.

Authors:  J M Davis; B Gylseth; A Morgan
Journal:  Thorax       Date:  1986-03       Impact factor: 9.139

9.  An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos.

Authors:  Y I Baris; N Bilir; M Artvinli; A A Sahin; F Kalyoncu; P Sebastien
Journal:  Br J Ind Med       Date:  1988-12

Review 10.  Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma.

Authors:  Ken Donaldson; Fiona A Murphy; Rodger Duffin; Craig A Poland
Journal:  Part Fibre Toxicol       Date:  2010-03-22       Impact factor: 9.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.